Several leading autism organisations in the UK have spoken out against new claims from the US suggesting that paracetamol use during pregnancy could increase the risk of autism in children. Ambitious about Autism, Autism Alliance, Autistica, and the National Autistic Society said the evidence behind the claims is “very weak” and based on flawed studies. They pointed to well-conducted research showing no credible link, urging expectant parents to continue following NHS advice on safe medication use in pregnancy.

The claims came from the US Department of Health and Human Services during an event led by President Donald Trump and HHS Secretary Robert F. Kennedy, Jr. The announcement included warnings about paracetamol (acetaminophen) and outlined new steps for addressing autism. While the US Food and Drug Administration acknowledged conflicting research, it advised doctors to use the lowest effective dose when prescribing paracetamol to pregnant women, balancing potential risks against the dangers of untreated fever.

The FDA also signaled plans to expand the use of leucovorin, a folate-based treatment, for children with autism who show speech-related challenges. Early studies suggest leucovorin may improve language and social abilities in certain cases, though experts stressed it is not a cure and must be combined with other therapies. Larger clinical trials are now being planned by the National Institutes of Health.

UK charities emphasised that there is no drug or therapy that “cures” autism and criticised repeated inaccurate claims from the Trump administration. They argued that rising autism rates reflect better awareness and improved diagnosis, not environmental causes. Experts warn that misleading statements risk stigmatizing autistic people and distracting from vital research focused on support and inclusion.